CVS Caremark, Generation Health Unveil 13 Drugs for PGx Testing Program, But Not Warfarin | GenomeWeb

By Turna Ray

CVS Caremark this week announced the 13 drugs for which the pharmacy services provider will provide pharmacogenomic testing as part of a pilot program slated for launch in July.

Although CVS Caremark is offering PGx testing for many of the drugs that competitor Medco includes in its service, one major difference is that CVS Caremark will not be offering genetic testing to gauge warfarin sensitivity.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.